Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Scie…
Biotechnology
US, Minneapolis [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | -6.68 | 4.08 | 4.37 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -44.98 | 3.57 | 6.50 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| Book Value | 2.73 | 12.81 | 12.46 | |
| Cash | 7.27 | 0.92 | 0.86 | |
| Capex | -10.77 | -0.10 | -0.09 | |
| Free Cash Flow | -5.30 | 0.41 | 0.43 | |
| Revenue | 11.47 | 1.93 | 1.73 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 4.42 | 0.68 | 0.65 | |
| Operating Margin | 70.16 | 0.24 | 0.14 | |
| ROA | 79.25 | 0.02 | 0.01 | |
| ROE | 74.12 | 0.02 | 0.01 | |
| ROIC | 92.79 | 0.02 | 0.01 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of TECH is permitted for members.
5
Growth
The "Growth Entry" for the Focus of TECH is permitted for members.
6
Leverage & Liquidity